Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Alternating between oral and topical minoxidil is considered, with concerns about staining bed sheets. Oral minoxidil may cause more body hair but is less messy than topical.

Finasteride is expensive in Europe, with users suggesting buying 5mg pills and splitting them to save money. Prices vary by country, and some recommend using telemedicine or buying from other countries to reduce costs.

The user has been using 5% minoxidil foam for 5 months with noticeable results and is considering adding finasteride. Suggestions include adding finasteride, using hair fiber spray, and trying microneedling for better results.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

A user has been using a new brand of minoxidil called VIOFAIRY for six months and finds it effective, though the labeling has misspellings. They are seeking feedback from others who have tried this brand.

Dutasteride tablets are considered by some to be as effective as soft gel capsules, with opinions differing on their bioavailability and absorption. Some users report positive results using tablets, while others suggest soft gels or combining with other treatments like minoxidil for better outcomes.

A user is searching for a specific scalp applicator with a plunger-style button to effectively dispense Minoxidil. They found it out of stock but received help from another user who provided a link to the desired product.

A 21-year-old started treatment for androgenetic alopecia and seborrheic dermatitis with oral finasteride, topical minoxidil, anti-dandruff shampoo, and a corticosteroid solution. After 1.5 months, they noticed increased hair density and are considering switching to oral minoxidil due to scalp issues.

The user is experiencing hair regrowth after three months using minoxidil, 1.25mg finasteride, ketoconazole cream, and a 1.5mm derma roller. They are considering reducing their finasteride dose due to decreased libido.

The applicator for a homemade hair loss solution containing Minoxidil, RU58841, Azelaic acid, and caffeine is difficult to use, with users experiencing issues with dispensing the liquid. Some suggest pressing harder or using a different method, like a dropper, for better application.

A user is documenting their natural approach to treating a receding hairline using a dermastamp, essential oils (rosemary oil at 3% dilution with pumpkin seed oil), a multivitamin with vitamin D, and daily collagen shakes. They acknowledge the common recommendations of minoxidil and finasteride but prefer to test natural methods and share their results.

A user shared their successful hair loss regimen, which includes New Nordic Hair Gro vitamins, Shea Moisture Jamaican Black Castor Oil Leave-In Conditioner, and NAC supplements. They reported reduced hair shedding, thicker hair, and improved hair texture.

Significant hair regrowth was achieved over six years using Minoxidil, Finasteride, and daily 0.25mm dermarolling. Finasteride had the most significant impact, with no reported side effects.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

Finasteride and minoxidil are discussed as hair loss treatments, with mixed opinions on side effects like sexual dysfunction and mood changes. Some users report positive results, while others express concerns about potential risks and insufficient information.

The conversation expresses frustration over the lack of clear evidence regarding the effectiveness and systemic impact of topical Dutasteride for hair loss treatment, despite years of discussion. People are criticized for not conducting proper research and for providing contradictory anecdotal claims.

The conversation discusses hair regrowth using minoxidil and dutasteride, with users sharing their experiences and results. Some users report improvements, while others mention side effects like low libido and erectile dysfunction.

A 36-year-old considering a fourth hair transplant is advised to either shave his head or use a hair system due to poor results from previous transplants and late medication use. He plans to consult top surgeons and adjust his current treatments, including finasteride and minoxidil.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

VDPHL01 is discussed as a potential replacement for DHT blockers, with comparisons to minoxidil. Users express skepticism about its effectiveness without addressing DHT, suggesting it may only slow hair loss rather than stop it.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.